Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 8 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
The Broad Institute Inc. has 7 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 7 pending office actions are distributed among 7 distinct examiners, ensuring that no two cases are currently being reviewed by the same person. This distribution across 7 distinct examiners indicates a broad exposure to different examination styles within the patent office. For the institute, this means that 7 independent prosecution tracks are being managed simultaneously.
The portfolio shows a high degree of technical specialization, with 7 distinct art units for only 7 pending office actions. HALVORSON, MARK is the busiest examiner with 1 pending office action, a count shared by all other examiners. The fact that each of the 7 pending office actions resides in one of 7 distinct art units suggests that each filing represents a unique technical niche within the biotechnology field. This relationship between 7 pending office actions, 7 distinct examiners, and 7 distinct art units reflects a highly fragmented prosecution landscape. Practitioners must navigate 7 different sets of art unit guidelines and 7 individual examiner preferences to advance these 7 pending office actions.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (12%) |
| §103 only | 2 (25%) |
| §112 only | 2 (25%) |
| Multi-statute (no §101) | 3 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HALVORSON, MARK | 1 | 47.9% | +20.7% |
| BARSKY, JARED | 1 | 50.2% | +22.7% |
| PAGUIO FRISING, MICHELLE F | 1 | 71.1% | +39.3% |
| KOVACH, KARA NICOLE | 1 | 85.7% | +100.0% |
| IVANOVA, SVETLANA M | 1 | 50.9% | +51.5% |
| POPA, ILEANA | 1 | 21.4% | +15.1% |
| LAFAVE, ELIZABETH ROSE | 1 | 62.5% | +45.4% |
| BEHARRY, ZANNA MARIA | 1 | 24.7% | +56.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18446945 | COMPOSITIONS FOR DETECTING SECRETION AND METHODS OF USE | POPA, ILEANA | 26d |
| 18548580 | FABI INHIBITORS FOR GRAM-NEGATIVE PATHOGENS | IVANOVA, SVETLANA M | 54d |
| 18580579 | COMPOSITIONS AND METHODS FOR CHARACTERIZING A COMPLEX BIOLOGICAL SAMPLE | KOVACH, KARA NICOLE | — |
| 17927112 | NUCLEIC ACID ARTIFICIAL MINI-PROTEOME LIBRARIES | LAFAVE, ELIZABETH ROSE | — |
| 17615579 | REPRODUCIBLE BRAIN ORGANOIDS AND METHODS OF MAKING | BEHARRY, ZANNA MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19074044 | FORMULATIONS FOR NEOPLASIA VACCINES | HALVORSON, MARK | 5d |
| 18446945 | COMPOSITIONS FOR DETECTING SECRETION AND METHODS OF USE | POPA, ILEANA | 26d |
| 18548580 | FABI INHIBITORS FOR GRAM-NEGATIVE PATHOGENS | IVANOVA, SVETLANA M | 54d |
| 18622123 | GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS FOR TREATING CTNNB1 SYNDROME | BARSKY, JARED | — |
| 18690382 | SUBSTRATES AND BIOMARKERS OF ADAMTS7 | PAGUIO FRISING, MICHELLE F | — |
| 18580579 | COMPOSITIONS AND METHODS FOR CHARACTERIZING A COMPLEX BIOLOGICAL SAMPLE | KOVACH, KARA NICOLE | — |
| 17927112 | NUCLEIC ACID ARTIFICIAL MINI-PROTEOME LIBRARIES | LAFAVE, ELIZABETH ROSE | — |
| 17615579 | REPRODUCIBLE BRAIN ORGANOIDS AND METHODS OF MAKING | BEHARRY, ZANNA MARIA | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1628 | 1 |
| 1651 | 1 |
| 1681 | 1 |
| 1627 | 1 |
| 1633 | 1 |
| 1684 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19074044 | FORMULATIONS FOR NEOPLASIA VACCINES | HALVORSON, MARK | 1646 | §112 | Final Rejection | 5d | Pending | Mar 07, 2025 |
| 18622123 | GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS FOR TREATING CTNNB1 SYNDROME | BARSKY, JARED | 1628 | §103 | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18690382 | SUBSTRATES AND BIOMARKERS OF ADAMTS7 | PAGUIO FRISING, MICHELLE F | 1651 | §112 | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18580579 | COMPOSITIONS AND METHODS FOR CHARACTERIZING A COMPLEX BIOLOGICAL SAMPLE | KOVACH, KARA NICOLE | 1681 | §101§103§112 | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18548580 | FABI INHIBITORS FOR GRAM-NEGATIVE PATHOGENS | IVANOVA, SVETLANA M | 1627 | §102§103§112 | Final Rejection | 54d | Pending | Sep 01, 2023 |
| 18446945 | COMPOSITIONS FOR DETECTING SECRETION AND METHODS OF USE | POPA, ILEANA | 1633 | §103 | Final Rejection | 26d | Pending | Aug 09, 2023 |
| 17927112 | NUCLEIC ACID ARTIFICIAL MINI-PROTEOME LIBRARIES | LAFAVE, ELIZABETH ROSE | 1684 | §103§112 | Non-Final OA | — | Pending | Nov 22, 2022 |
| 17615579 | REPRODUCIBLE BRAIN ORGANOIDS AND METHODS OF MAKING | BEHARRY, ZANNA MARIA | 1632 | §103§112 | Final Rejection | — | Pending | Nov 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial